Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

246
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
246
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

726
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
726
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Lipid Catabolism01:25

Lipid Catabolism

1.3K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.3K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: analysis of physician-reported charts.

Journal of comparative effectiveness research·2026
Same author

Design of an integrated evidence-driven few-shot meta-learning for zero-day malware detection and forensic attributions.

Scientific reports·2026
Same author

American Foregut Society Education Committee: Development Of The Advanced Foregut Fellowship Program for Gastroenterology Trainees.

Foregut (Thousand Oaks, Calif.)·2026
Same author

American Society for Gastrointestinal Endoscopy standards for fellowship training in peroral endoscopic myotomy.

Gastrointestinal endoscopy·2026
Same author

Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.

The American journal of gastroenterology·2026
Same author

Symptomatic Sarcoidosis Treated with Acthar<sup>®</sup> Gel: Insights from a Physician-Reported Chart Review.

Pulmonary therapy·2026

Related Experiment Video

Updated: Mar 9, 2026

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Genotype specific peripheral lipid profile changes with hepatitis C therapy.

Mark R Pedersen1, Amit Patel1, David Backstedt1

  • 1Mark R Pedersen, Department of Internal Medicine, Banner University Medical Center, University of Arizona College of Medicine, Phoenix, AZ 85006, United States.

World Journal of Gastroenterology
|December 29, 2016
PubMed
Summary
This summary is machine-generated.

Direct-acting antiviral therapy for hepatitis C significantly alters lipid profiles, increasing total cholesterol, LDL, and HDL, while decreasing triglycerides, especially in genotypes 1 and 3. Genotype 3 shows the most pronounced changes.

Keywords:
Hepatitis C genotypesLipidsMetabolic syndrome

More Related Videos

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 9, 2026

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis
10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Area of Science:

  • Hepatology
  • Virology
  • Clinical Lipidology

Background:

  • Hepatitis C virus (HCV) infection can impact lipid metabolism.
  • Direct-acting antivirals (DAAs) have revolutionized HCV treatment, leading to high sustained virologic response rates.
  • The effects of DAA therapy on peripheral lipid profiles, stratified by HCV genotype, require detailed evaluation.

Purpose of the Study:

  • To investigate the magnitude and direction of changes in peripheral lipid profiles (total cholesterol, HDL, LDL, triglycerides) in patients treated with DAAs for hepatitis C.
  • To compare these lipid profile alterations across different hepatitis C genotypes (GT1, GT2, GT3).

Main Methods:

  • A cohort of hepatitis C mono-infected patients receiving guideline-based DAAs was studied.
  • Lipid profiles and liver function tests were measured pre-treatment and post-treatment (ETR).
  • Statistical analyses, including Levene's test, student's t test, ANOVA, and post-hoc tests, were used to compare lipid changes between genotypes.

Main Results:

  • Sustained virologic response was achieved in 85.6% of 375 enrolled patients.
  • Significant increases in total cholesterol (TCHOL), HDL, and LDL, and a decrease in triglycerides (TG) were observed in GT1 and GT3.
  • Genotype 3 demonstrated the most significant increases in TCHOL and HDL compared to GT1 and GT2.

Conclusions:

  • Successful DAA therapy for hepatitis C leads to significant favorable changes in lipid profiles, including increased TCHOL, LDL, and HDL, and decreased TG.
  • These lipid profile modifications are particularly notable in patients with GT1 and GT3 infections.
  • The most substantial alterations in lipid parameters are observed in patients with hepatitis C genotype 3.